ArticleJournal of orthopaedic case reports2026
Ceftazidime-Avibactam/Aztreonam Combination for the Treatment of Carbapenem-resistant Klebsiella pneumoniae-induced Osteomyelitis: A Case Series with Review of Literature.
Article in Journal of orthopaedic case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Osteomyelitis secondary to multi-drug resistant (MDR) gram-negative bacteria (GNB), especially Carbapenem-resistant Klebsiella pneumoniae (CRKP), is a rare occurrence. These are difficult to treat micro-organisms and their presence within the host bone tissue makes them inherently resistant to most standard antimicrobials. Although a number of drugs have been described in the literature, there are no standardized guidelines as to the ideal drug of choice effective against CRKP-induced bone and joint infections (BJIs). In this context, we have described our experience in treating three cases of CRKP osteomyelitis secondary to an open fracture, who presented to us following a road-traffic accident (RTA). Case Report: Three patients of polytrauma presented to the emergency room of a tertiary care institute following RTA. All of them were primarily resuscitated, following which fixation of the fractures was undertaken. In the post-operative period, surgical site infection was seen in all three at specific locations. These were thoroughly debrided, and intraoperative samples sent for culture analyses. The latter revealed isolates of CRKP. Accordingly, a multidisciplinary approach was followed, combining inputs from the surgical team, clinical microbiologist, as well as an infectious disease specialist. Infected implants were removed, and a plastic surgery consult sought for wound coverage. Ceftazidime-Avibactam (CAZ-AVI) in conjunction with Aztreonam (ATM) was started after synergy testing. This was continued for a duration of 4-6 weeks. In two patients, the fracture had successfully united, whereas in one, a definitive fixation is still pending. Soft-tissue envelope healing was achieved in all cases. No adverse effects were reported. Conclusion: Cases of BJI secondary to CRKP necessitate a combined approach which includes prompt surgical debridement with/without implant removal and culture-specific antimicrobial therapy. Although experience is limited, CAZ-AVI/ATM combination has shown promising results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.